Compare INOD & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | NVCR |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | Switzerland |
| Employees | 3000 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1996 | 2015 |
| Metric | INOD | NVCR |
|---|---|---|
| Price | $67.62 | $16.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $100.00 | $28.08 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.37 | ★ 21.79 |
| EPS | ★ 0.42 | N/A |
| Revenue | $86,775,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $38.42 | $7.72 |
| Revenue Next Year | $27.03 | $6.74 |
| P/E Ratio | $164.71 | ★ N/A |
| Revenue Growth | ★ 9.84 | 8.28 |
| 52 Week Low | $34.23 | $9.82 |
| 52 Week High | $125.14 | $18.92 |
| Indicator | INOD | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 50.50 |
| Support Level | $67.40 | $12.49 |
| Resistance Level | $114.30 | $18.59 |
| Average True Range (ATR) | 5.45 | 0.92 |
| MACD | -2.05 | 0.16 |
| Stochastic Oscillator | 5.41 | 65.48 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.